The table below displays the digital pathway rule logic for the conditions that have been identified for call and recall for the COVID-19 Autumn Booster Vaccinations 2022-23. These conditions are detailed in Chapter 14a of the Green Book.
Currently GPES data is being pulled from GPES v4 and GDPPR. GPES data will be more comprehensive when GPES v5 extract becomes available at the end of November 2022.
Asplenia or dysfunction of the spleen
| Description | Data used | Rulesets |
|---|---|---|
| Homozygous sickle cell disease and hereditary spherocytosis. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with homozygous sickle cell disease and hereditary spherocytosis. |
| Asplenia; splenic dysfunction such as thalassemia major and coeliac syndrome. |
GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with asplenia or splenic dysfunction including thalassemia major and coeliac disease. |
Chronic heart disease
| Description | Data used | Rulesets |
|---|---|---|
| Congenital heart disease, hypertension with cardiac complications, and chronic heart failure. |
GPESv4, GDPPR, GPESv5, HES, OPCS | All people aged 5 years and over with congenital heart disease, hypertension with cardiac complications, pulmonary hypertension, or chronic heart failure. |
| Individuals requiring regular medication and/or follow-up for ischaemic heart disease this includes atrial fibrillation, peripheral vascular disease, or a history of venous thromboembolism. | GPESv4, GDPPR, GPESv5, HES | All people aged 16 years and over with a diagnosis of ischaemic heart disease including atrial fibrillation, peripheral vascular disease, or history of venous thromboembolism (irrespective of treatment or follow-up). |
Chronic kidney disease
| Description | Data used | Rulesets |
|---|---|---|
| Chronic kidney disease at stage 3, 4 or 5; chronic kidney failure; nephrotic syndrome; and kidney transplantation. | GPESv4, GDPPR, GPESv5, HES, OPCS | All people aged 5 years and over with a diagnosis of chronic kidney disease at stage 3, 4 or 5 (not superseded by a stage 1/2 diagnosis); people on renal dialysis; diagnosis of nephrotic syndrome; or history or renal transplant. |
Chronic liver disease
| Description | Data used | Rulesets |
|---|---|---|
| Cirrhosis, biliary atresia, and chronic hepatitis. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with a diagnosis of liver cirrhosis, biliary atresia or chronic hepatitis. |
Chronic kidney and liver disease
| Description | Data used | Rulesets |
|---|---|---|
| Congenital malformations of the organs, metabolic disorders and neoplasms, and conditions such as severe gastroesophageal reflux that may predispose to respiratory infection. | GPESv4, GDPPR, GPESv5, HES | Children aged 5 to 15 years with a diagnosis of congenital malformation of the organs, or metabolic diseases. |
Chronic neurological disease
| Description | Data used | Rulesets |
|---|---|---|
| Conditions in which respiratory function may be compromised due to neurological or neuromuscular disease (e.g. polio syndrome sufferers). This group also includes individuals with cerebral palsy, severe or profound and multiple learning disabilities (PMLD), Down’s syndrome, multiple sclerosis, epilepsy, dementia, Parkinson’s disease, motor neurone disease and related or similar conditions. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with neurological conditions where respiratory compromise is variable such as Parkinson's disease, motor neurone disease, Huntington's chorea; and rare neurological diseases which may be associated with respiratory compromise. |
| Stroke or transient ischaemic attack (TIA). | GPESv4, GDPPR, GPESv5, HES | All people 5 years and over with a history of stroke or transient ischaemic attack (TIA). |
| Learning disabilities including severe or profound and multiple learning disabilities (PMLD), Down's syndrome and those on the learning disability register. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with a learning disability. |
| Other rare neurological diseases. Hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with rare neurological conditions such as hereditary or degenerative diseases of the nervous system or muscles. |
| Neurodisability and/or neuromuscular disease that may occur as a result of conditions such as cerebral palsy, autism, epilepsy and muscular dystrophy. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with neurodisability and/or neuromuscular diseases such as those as a result of cerebral palsy, autism, epilepsy or muscular dystrophy. |
| Neoplasm of the brain. | GPESv4, GDPPR, GPESv5, HES | Children aged 5 to 15 years with a brain neoplasm. People over 16 are identified via their treatment records. |
Chronic respiratory disease
| Description | Data used | Rulesets |
|---|---|---|
| Those with poorly controlled asthma (≥2 courses of oral corticosteroids in the preceding 24 months or those with poorly controlled asthma on maintenance oral corticosteroids within the last month). | GPESv4, GDPPR, GPESv5, HES | All people over 5 who have been prescribed four steroid prescriptions on separate days in the last 6 months. |
| Those with poorly controlled asthma (≥1 hospital admission for asthma in the preceding 24 months). | GPESv4, GDPPR, GPESv5 | All people aged 5 years and over with a hospital admission due to asthma in the last 24 months recorded in their GP records. |
| Individuals with a severe lung condition chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema; bronchiectasis, interstitial lung fibrosis, pneumoconiosis. | GPESv4, GDPPR, GPESv5, HES | All people aged 16 years and over with a diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, interstitial lung disease or pneumoconiosis. |
| Cystic fibrosis. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with a diagnosis of cystic fibrosis. |
| Bronchopulmonary dysplasia (BPD). | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with Bronchopulmonary dysplasia. |
| Ciliary dyskinesias. | See non-digital pathway. |
Endocrine
| Description | Data used | Rulesets |
|---|---|---|
| Any diabetes including diet-controlled, current gestational diabetes, and Addison's disease. |
GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with a diagnosis of diabetes mellitus or Addison's disease. Gestational diabetes diagnosed within the last 6 months. |
| Hypopituitary syndrome. | GPESv4, GDPPR, GPESv5, HES | Children aged 5 to 15 years with hypopituary syndrome. |
Immunosuppression
| Description | Data used | Rulesets |
|---|---|---|
| Genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID). | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with genetic disorders affecting the immune system, or a chromosomal disorder, or a primary or acquired immune deficiency. |
| Serious genetic abnormalities that affect a number of systems. | GPESv4, GDPPR, GPESv5, HES | Children aged 5 to 15 years with serious genetic abnormalities including those diagnosed with mitochondrial disease and chromosomal abnormalities. |
| Patients undergoing chemotherapy leading to immunosuppression and patients undergoing radical radiotherapy. | GPESv4, GDPPR, GPESv5, OPCS, SACT, RTDS | Chemotherapy and/or radiotherapy within the last 12 months recorded via SACT (chemotherapy), RTDS (radiotherapy) databases or via GP records. CAR-T treatment recorded in the GP record within the last 24 months. |
| Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults, and children treated with or likely to be treated with high or moderate dose corticosteroids. | GPESv4, GDPPR, GPESv5 | All people aged 5 years and over who have been prescribed four steroid prescriptions on separate days in the last 6 months. |
| Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil. | GPESv4, GDPPR, GPESv5 | All people aged 5 years and over receiving immunosuppresive or immunomodulating biological therapies including biological treatment of B cell lymphoma in the last 12 months. |
|
Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis. |
GPESv4, GDPPR, GPESv5 | All people aged 5 years and over who have been prescribed immunosuppressive and non-biological immune modulating drugs including but not limited to methotrexate, azathioprine, hydroxychloroquine, tacrolimus, sulfasalazine, mercaptopurine or mycophenolate. |
| Solid organ transplant recipients. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over who have received a solid organ transplant. |
| Human immunodeficiency virus (HIV) infection at all stages, and other specified immunodeficiencies. | GPESv4, GDPPR, GPESv5, HES | All people aged 5 years and over with HIV, acquired autoimmune deficiency (AIDs), and other immunodeficiencies. |
| People with a history of haematological malignancy including leukaemia, lymphoma and myeloma/multiple myeloma. | GPESv4, GDPPR, GPESv5, HES, SACT | All people aged 5 years and over with a history of haematological malignancy including leukaemia, lymphoma and myeloma. |
| Bone marrow or stem cell transplant recipients. | GPESv4, GDPPR, GPESv5, HES, OPCS | All people aged 5 years and over who are bone marrow or stem cell transplant recipients including all people with graft versus host disease. |
Morbid obesity
| Description | Data used | Rulesets |
|---|---|---|
| Adults with a body mass index (BMI) codes >= 40kg/m^2. | GPESv4, GDPPR, GPESv5 | All people aged 16 years and over with a body mass index greater or equal to 40kg/m^2 recorded in the last 5 years with no subsequent recorded BMI measurement lower than 40. |
Severe mental illness
| Description | Data used | Rulesets |
|---|---|---|
| Individuals with schizophrenia, bipolar disorder or any mental illness that causes severe functional impairment. | GPESv4, GDPPR, GPESv5, HES | All people aged 16 years and over with a diagnosis of schizophrenia, bipolar disorder, or mental illnesses which may lead to severe functional impairment. |
Pregnancy
| Description | Data used | Rulesets |
|---|---|---|
| All stages (first, second and third trimesters). | See non-digital pathway. |
Last edited: 25 October 2022 3:13 pm